Latest news

• Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

  This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera. ... With Remsima, we achieved market

• Roche faces biosimilar blitz in 2018

  Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab).

• Roche faces prospect of second Rituxan biosimilar in US

  It was the second biosimilar of Roche's drug to be approved in Europe after Celltrion/Mundipharma's Truxima, which also pipped Sandoz to the filing post in the US after

• Standing out in a crowd

  It followed that this year by gaining approval from the European Commission for the world’s first monoclonal antibody biosimilar of MabTera (rituximab), marketed as Truxima.

• Sandoz joins Europe's MabThera biosimilar push

  The approval - which comes four months after Celltrion/Mundipharma's Truxima biosimilar was cleared for marketing by the EMA - is for the entire range of indications awarded to MabThera, including ... Truxima claimed the distinction of being the first